Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem and Ciprofloxacin Dosing in Critically Ill Patients with Septic Shock
2014-002555-26Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Jun 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of meropenem and ciprofloxacin in septic shock and sepsis, sponsored by Rigshospitalet. Primary endpoint: Pharmacokinetic profiles of meropenem and ciprofloxacin. Started Jun 2014; status: completed.
02
Drugs
meropenemciprofloxacin
03
Conditions
septic shocksepsis
Beyond the preview
Go deeper on 2014-002555-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002555-26.